دورية أكاديمية
أعرض في EDS

Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.

التفاصيل البيبلوغرافية
العنوان: Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
المؤلفون: Chen SY; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia., Beretta M; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia., Olzomer EM; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia., Alexopoulos SJ; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia., Shah DP; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia., Byrne FL; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia., Salamoun JM; Department of Chemistry and Virginia Tech Centre for Drug Discovery, Virginia Tech, Blacksburg, VA 24061, USA., Garcia CJ; Department of Chemistry and Virginia Tech Centre for Drug Discovery, Virginia Tech, Blacksburg, VA 24061, USA., Smith GC; School of Medical Science, University of New South Wales, Sydney, NSW 2052, Australia., Larance M; Charles Perkins Centre, School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia., Philp A; Charles Perkins Centre, School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia; Centre for Healthy Ageing, Centenary Institute, Camperdown, NSW 2050, Australia; School of Sport, Exercise and Rehabilitation Sciences, Faculty of Health, University of Technology Sydney, Sydney, NSW 2007, Australia., Turner N; Cellular Bioenergetics Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia., Santos WL; Department of Chemistry and Virginia Tech Centre for Drug Discovery, Virginia Tech, Blacksburg, VA 24061, USA., Cantley J; School of Medicine, University of Dundee, Dundee DD1 4HN, UK., Hoehn KL; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: k.hoehn@unsw.edu.au.
المصدر: Biochimica et biophysica acta. Molecular basis of disease [Biochim Biophys Acta Mol Basis Dis] 2024 Jan; Vol. 1870 (1), pp. 166908. Date of Electronic Publication: 2023 Oct 02.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101731730 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-260X (Electronic) Linking ISSN: 09254439 NLM ISO Abbreviation: Biochim Biophys Acta Mol Basis Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Elsevier
مواضيع طبية MeSH: Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/metabolism , Non-alcoholic Fatty Liver Disease*/metabolism, Mice ; Animals ; Female ; Niclosamide/therapeutic use ; Rosiglitazone/pharmacology ; Rosiglitazone/therapeutic use ; Ethanolamine/therapeutic use ; Caloric Restriction ; Ethanolamines/therapeutic use ; Obesity/drug therapy ; Obesity/metabolism
مستخلص: Metabolic disorders such as type 2 diabetes, fatty liver disease, hyperlipidemia, and obesity commonly co-occur but clinical treatment options do not effectively target all disorders. Calorie restriction, semaglutide, rosiglitazone, and mitochondrial uncouplers have all demonstrated efficacy against one or more obesity-related metabolic disorders, but it currently remains unclear which therapeutic strategy best targets the combination of hyperglycaemia, liver fat, hypertriglyceridemia, and adiposity. Herein we performed a head-to-head comparison of 5 treatment interventions in the female db/db mouse model of severe metabolic disease. Treatments included ∼60 % calorie restriction (CR), semaglutide, rosiglitazone, BAM15, and niclosamide ethanolamine (NEN). Results showed that BAM15 and CR improved body weight and liver steatosis to levels superior to semaglutide, NEN, and rosiglitazone, while BAM15, semaglutide, and rosiglitazone improved glucose tolerance better than CR and NEN. BAM15, CR, semaglutide, and rosiglitazone all had efficacy against hypertriglyceridaemia. These data provide a comprehensive head-to-head comparison of several key treatment strategies for metabolic disease and highlight the efficacy of mitochondrial uncoupling to correct multiple facets of the metabolic disease milieu in female db/db mice.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kyle Hoehn reports financial support was provided by National Institutes of Health and National Health and Medical Research Council. Kyle Hoehn reports a relationship with Uncoupler Therapeutics, Inc. that includes: board membership and equity or stocks. Kyle Hoehn reports a relationship with Life Biosciences, Inc. that includes: equity or stocks. Kyle Hoehn has a patent via University of Virginia. Webster Santos reports financial support was provided by National Institutes of Health. Webster Santos reports a relationship with Uncoupler Therapeutics, Inc. that includes: board membership and equity or stocks. Webster Santos reports a relationship with Life Biosciences, Inc. that includes: equity or stocks.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
References: Int J Exp Pathol. 2011 Dec;92(6):413-21. (PMID: 22118645)
Biol Sex Differ. 2012 May 31;3(1):13. (PMID: 22651247)
Nat Commun. 2020 May 14;11(1):2397. (PMID: 32409697)
Cien Saude Colet. 2018 Aug;23(8):2565-2574. (PMID: 30137126)
Physiol Behav. 2018 Apr 1;187:20-23. (PMID: 28843891)
PLoS One. 2021 Oct 21;16(10):e0258942. (PMID: 34673835)
RSC Adv. 2020 Feb 24;10(14):8044-8053. (PMID: 35497855)
Cell Metab. 2013 Nov 5;18(5):740-8. (PMID: 24206666)
Sci Rep. 2019 Jan 29;9(1):881. (PMID: 30696927)
JCI Insight. 2020 Mar 26;5(6):. (PMID: 32213703)
Diabetes. 2019 Dec;68(12):2197-2209. (PMID: 31471292)
Front Nutr. 2022 Feb 17;9:828522. (PMID: 35284452)
N Engl J Med. 2013 Oct 3;369(14):1285-7. (PMID: 23992603)
Diabetol Int. 2021 Feb 07;12(4):399-404. (PMID: 34567922)
Gastroenterology. 2008 Jul;135(1):100-10. (PMID: 18503774)
Nat Med. 2014 Nov;20(11):1263-9. (PMID: 25282357)
Nat Commun. 2019 May 15;10(1):2172. (PMID: 31092829)
Diabetologia. 2001 Dec;44(12):2210-9. (PMID: 11793023)
Sci Transl Med. 2019 Oct 2;11(512):. (PMID: 31578240)
Elife. 2016 Mar 03;5:. (PMID: 26939790)
Rev Endocr Metab Disord. 2022 Jun;23(3):521-539. (PMID: 34993760)
Obesity (Silver Spring). 2022 Apr;30(4):841-857. (PMID: 35333444)
J Biol Chem. 1995 Jun 2;270(22):12953-6. (PMID: 7768881)
Lancet. 2006 Sep 23;368(9541):1096-105. (PMID: 16997664)
J Biol Chem. 1957 May;226(1):497-509. (PMID: 13428781)
Science. 2015 Mar 13;347(6227):1253-6. (PMID: 25721504)
J Med Chem. 2018 Jun 14;61(11):4641-4655. (PMID: 29156129)
J Diabetes Res. 2017;2017:8503754. (PMID: 29038790)
PLoS One. 2013 Apr 30;8(4):e62833. (PMID: 23646149)
Diabetes. 2017 Aug;66(8):2092-2101. (PMID: 28506962)
Gen Pharmacol. 1997 Feb;28(2):273-99. (PMID: 9013207)
Front Endocrinol (Lausanne). 2021 Aug 23;12:721135. (PMID: 34497589)
EMBO Mol Med. 2020 Jul 7;12(7):e12088. (PMID: 32519812)
N Engl J Med. 2021 Mar 18;384(11):989-1002. (PMID: 33567185)
Lancet Diabetes Endocrinol. 2021 Sep;9(9):563-574. (PMID: 34293304)
PLoS One. 2013 Dec 06;8(12):e82813. (PMID: 24324833)
Mol Metab. 2023 Mar;69:101684. (PMID: 36731653)
معلومات مُعتمدة: R01 DK128612 United States DK NIDDK NIH HHS; R25 GM072767 United States GM NIGMS NIH HHS
فهرسة مساهمة: Keywords: Calorie restriction; Diabetes; GLP-1; Mitochondrial uncoupling; Obesity
المشرفين على المادة: 8KK8CQ2K8G (Niclosamide)
05V02F2KDG (Rosiglitazone)
5KV86114PT (Ethanolamine)
53AXN4NNHX (semaglutide)
0 (Ethanolamines)
تواريخ الأحداث: Date Created: 20231004 Date Completed: 20231113 Latest Revision: 20240303
رمز التحديث: 20240303
مُعرف محوري في PubMed: PMC10908303
DOI: 10.1016/j.bbadis.2023.166908
PMID: 37793464
قاعدة البيانات: MEDLINE
الوصف
تدمد:1879-260X
DOI:10.1016/j.bbadis.2023.166908